Question-and-Answer Session
Operator
Thank you. We will now begin the question and answer session. [Operator Instructions]. Your first question comes from Brian White from Deutsche Bank. Please ask your question.
Brian White - Deutsche Bank AG London
Good afternoon. Just a couple of quick questions. Firstly, looking at the data you've supplied, based on the reception to VYVANSE, does this mean that there's really no need for products like INTUNIV in the future? I guess, we haven't had much of an update on that for a while. And then just secondly, have you seen much off-label usage of VYVANSE in adults?
Matthew Emmens - Chief Executive Officer and Chairman of the Management Committee
Yes, Brian, I'll answer those backwards for you. Generally, ADDERALL had about 40% adults, the last data I saw it was about 30% adults. For VYVANSE you know we can't promote this, it's just the physicians now believe that these drugs work in all kinds of patients. And we will have the indication and the ability to promote in April of next year. And the INTUNIV we believe has a place in the market. We have some interesting data on that product. As you know, we're in negotiations, we have an approvable letter. We haven't been in a big hurry to launch simply because we want to solve those things, get the best label we can. And in the meantime, it allows us to focus on VYVANSE, which I think is the superior opportunity.
Brian White - Deutsche Bank AG London
Okay, thank you.
Matthew Emmens - Chief Executive Officer and Chairman of the Management Committee
Thanks, Brian.
Operator
Your next question comes from Corey Davis from Natexis. Please ask your question.
Corey Davis - Natexis Bleichroeder Inc.
Thanks very much. I just have a couple of them. First, I realize JUVISTA is still a ways away, but... does it makes sense at some point, would you have to buy a commercial infrastructure to get into that market, i.e., a company already in that space or is it such a focused market that it's just as easy to set up your own sales force in that area?
Matthew Emmens - Chief Executive Officer and Chairman of the Management Committee
Yes, good question, Corey. We've certainly thought about it. Obviously, when you license a product that has that potential, you start to think about how you're going to do it. And we think we could do it either way. We're going to try to do it in a very thoughtful way. We haven't made any decisions on that yet. We certainly reviewed our alternatives and what the implications for cost and return might be. Stay tuned.
- To read the full transcript on Seeking Alpha, click here »
